LABS MediPharm Labs

MediPharm Labs Announces Participation at Upcoming Conferences

MediPharm Labs Announces Participation at Upcoming Conferences

BARRIE, Ontario, May 29, 2020 (GLOBE NEWSWIRE) -- MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its participation at upcoming virtual investor conferences.

  • Monday, June 1, 2020: Benzinga Cannabis Capital Conference
  • Wednesday, June 3, 2020: Jefferies Global Healthcare Conference

A link to the live audio webcast will be available prior to the start of the event and can be accessed through the events section of MediPharm Labs Investor Relations website at . An archived webcast will also be made available after the event.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:

Laura Lepore, VP, Investor Relations and Communications

Telephone: 416-913-7425 ext. 1525

Email:  

Website:  

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

 

EN
29/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediPharm Labs

 PRESS RELEASE

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Ov...

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue FY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025Company remains virtually debt-free, with outright ownership of two production facilitiesManagement to Host Conference Call / Webcast on March 30th, 2026, at 10:00 am ET TORONTO, March 30, 2026 (GLOBE NEWSWIRE...

 PRESS RELEASE

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 F...

MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026. MediPharm Labs executive management team will also host a conference call and webcast o...

 PRESS RELEASE

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; C...

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced that David Pidduck will be stepping down from his role as the Company's Chief Executive Officer, effective January 23rd, 2026. The Board of Directors (the "Board") has appointed Greg Hunter, the Company's Chief Financial Officer, as Interim Chief Executive Officer, wh...

 PRESS RELEASE

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement

MediPharm Labs to Enter New Market with Costa Rica Supply Agreement TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the signing of a definitive supply agreement with Remidose Aerosols Inc. (“Remidose”) for the shipment of GMP-certified medicinal cannabis products to Costa Rica. “MediPharm Labs’ proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannab...

 PRESS RELEASE

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportuni...

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump’s executive order  to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from Schedule I to Schedule III (the "Order")....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch